Hiv Testing And Treatment Articles & Analysis
14 news found
On July 15, 2021, The openning ceremony of a new state of the art peptide manufacture facility was held in Jintang, Chengdu. The successful completion of the facility marks the successful industrialization of Aikening® in Jintang. Aiming at intelligent manufacturing, high efficiency and eco system, and a quality system to be certified by the US FDA, EU EMA and China NMPA, the peptide ...
As the leading expert in computer-aided drug discovery, BOC Sciences has developed compound docking technologies to facilitate the discovery of novel ligands for over 30 targets. Has compound docking ever brought us medicine? This was generally questioned in the pharmaceutical industry. With many innovators like BOC Sciences springing up and improvements being made in computational chemistry, ...
Frontier Biotechnologies announced that the Azerbaijan Republic Ministry of Health approved Aikening® (Albuvirtide), the first long-acting intravenous infusion for the treatment of HIV-1 infection in adults. Aikening® is a new fusion inhibitor given once weekly, used in combination dual therapy to treat people living with HIV who have ...
Continued the recruitment for two Phase 2 clinical trials of BIT225 for treatment of HIV-1 infection at sites in Australia and Thailand. Continued the design, synthesis and testing of new compounds under its HIV-1 program, with the aim of identifying a next generation lead anti-HIV-1 drug. ...
Frontier Biotech (stock code: 688221.SH) announces that it signs an agreement with R-Pharm, JSC, one of the largest pharmaceutical companies in Russia, for registration and commercialization of Aikening® (generic name: Albuvirtide) in Russia. Cheryl Tan, Global Head of Frontier Biotech's International Businesses, said, “Aikening® is the first new long-acting antiretroviral drug ...
The TALENT study (TALENT) findings, which were presented at the 11th International AIDS Society (IAS) Conference on HIV Science, showed that a two-drug regimen was as effective and safe as multi-drug therapies TALENT is the world's first phase III clinical trial of the new long-acting HIV-1 fusion inhibitor, Aikening® (generic name: Albuvirtide [ABT]) in an all-Asian population TALENT ...
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering GPCR-targeted therapeutics, today announced the results of their Phase 1 study of OB-002H which is an investigational candidate microbicide for HIV prevention. The Phase 1 study was a first-in-man trial designed to evaluate the safety, acceptability, and pharmacokinetic profile of OB-002H ...
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced successful completion of participant follow-up in their Phase 1 study of OB-002H which is an investigational candidate microbicide. The Phase 1 study was a first-in-man trial designed to evaluate the safety, acceptability, and pharmacokinetic ...
New York, N.Y., October 22, 2013 -- Lauren Sciences LLC, a privately-held biotechnology company furthering development of V-Smart™ therapeutics based upon its novel nanovesicle platform technology, announced today successful completion by its research team at Ben-Gurion University of the first stage of developing a V-Smart™ therapeutic for the treatment of neuro-HIV. The development ...
Delayed test results often mean HIV patients in Mozambique fail to get timely treatment, but new technology is reducing the need to send tests to far away laboratories, and speeding up test results and HIV treatment. ...
Merck today announced The Merck Company Foundation and the Bill & Melinda Gates Foundation are committing an additional US$60 million to support Botswana's African Comprehensive HIV/AIDS Partnerships (ACHAP). Merck is known as MSD outside the US and Canada. A unique program developed with and led by the Government of Botswana, ACHAP is one of sub-Saharan Africa's oldest, most successful ...
Kaiser Permanente, one of the country's largest not-for-profit health care organizations, funded 700 grants nationwide totaling approximately $13 million in the second quarter of 2010. The grants this quarter focused on expanding access to healthy food, reducing childhood obesity, and increasing care for the underinsured. 'Kaiser Permanente is proud to partner with organizations that are ...
ViiV Healthcare today announced the launch of Positive Action U.S. Southern Initiative, a collaborative, community-focused program designed to address gaps in services or programs that support linkages to care and treatment adherence among individuals living with HIV/AIDS. The launch follows extensive consultations with some of the sector"s leading non-governmental organizations, practitioners ...
However, access to care and treatment for HIV-positive children remains woefully inadequate in many of these environments. ...